Hansa Biopharma AB announced the appointment of Dr. Richard Philipson as Chief Medical Officer effective July 14, marking a strategic leadership addition as the commercial-stage biopharmaceutical company prepares for its next development phase. Dr. Philipson will report to CEO Renée Aguiar-Lucander and serve as a member of the Executive Committee.
Extensive Industry Experience
Dr. Philipson brings over 25 years of industry experience with a proven track record in drug development. His clinical leadership has resulted in four product approvals, including treatments in rare disease and gene therapy. The new CMO demonstrates expertise in building high-functioning teams, developing pipelines, and executing clinical development programs across all phases of development.
"We are very pleased to welcome Dr Philipson to the executive management team as CMO. He brings invaluable experience in the area of drug development, from first-in-human to Phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development," said CEO Renée Aguiar-Lucander.
Career Background and Regulatory Expertise
Dr. Philipson's career includes significant roles at major pharmaceutical companies. He most recently served as CMO of Calliditas Therapeutics and previously spent 16 years at GlaxoSmithKline (GSK), including four years as Therapeutic Area Head in the Rare Diseases Unit. His experience also encompasses positions at Takeda and a four-year period as CMO at Trizell.
The appointment brings in-depth knowledge of regulatory strategy in drug development, which will be crucial for Hansa's upcoming regulatory submissions. Dr. Philipson expressed enthusiasm about joining the company at this critical juncture.
"I am excited to have the opportunity to join Hansa at this stage of the company's development. I look forward to working with the Hansa team and leveraging my experience from prior roles to support upcoming regulatory submissions and help build a strategic development plan for future indications," said Dr. Philipson.
Hansa's Technology Platform and Pipeline
Hansa Biopharma operates as a pioneering commercial-stage biopharmaceutical company focused on developing innovative treatments for patients with rare immunological conditions. The company's research and development program is built on its proprietary IgG-cleaving enzyme technology platform, addressing unmet medical needs in autoimmune diseases, gene therapy, and transplantation.
The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy that has demonstrated the ability to enable kidney transplantation in highly sensitized patients. Additionally, Hansa is developing HNSA-5487, a next-generation IgG cleaving molecule with redosing potential.
Based in Lund, Sweden, with operations in Europe and the United States, Hansa Biopharma is listed on Nasdaq Stockholm under the ticker HNSA. The company's mission focuses on developing lifesaving and life-altering treatments for patients with rare immunological conditions.
